Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials

Mody, 2018, Antiangiogenic therapy in colorectal cancer, Cancer J, 24, 165, 10.1097/PPO.0000000000000328 Ren, 2021, The combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer, Front Immunol, 12, 10.3389/fimmu.2021.689132 Chambers, 2021, Anti-angiogenesis revisited: combination with immunotherapy in solid tumors, Curr Oncol Rep, 23, 100, 10.1007/s11912-021-01099-7 Biller, 2021, Diagnosis and treatment of metastatic colorectal cancer: a review, J Am Med Assoc, 325, 669, 10.1001/jama.2021.0106 Van Cutsem, 2016, ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Ann Oncol, 27, 1386, 10.1093/annonc/mdw235 Van Cutsem, 2012, Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen, J Clin Oncol, 30, 3499, 10.1200/JCO.2012.42.8201 Folprecht, 2016, Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study, Ann Oncol, 27, 1273, 10.1093/annonc/mdw176 Tabernero, 2015, Lancet Oncol, 16, 499, 10.1016/S1470-2045(15)70127-0 Jang, 2017, The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials, Oncotarget, 8, 73009, 10.18632/oncotarget.20314 Itatani, 2018, Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway, Int J Mol Sci, 19, 1232, 10.3390/ijms19041232 Xue, 2021, Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment, BMC Cancer, 21, 1134, 10.1186/s12885-021-08859-5 Holmes, 2005, The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease, Genome Biol, 6, 209, 10.1186/gb-2005-6-2-209 Zhang, 2017, Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy, Proc Natl Acad Sci U S A, 114, E5226 De Falco, 2020, How we treat metastatic colorectal cancer, ESMO Open, 4 Jimenez, 2005, A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3, Mol Cancer Ther, 4, 427, 10.1158/1535-7163.MCT-04-0261 Yoshida, 2015, Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy?, Support Care Cancer, 23, 1623, 10.1007/s00520-014-2518-3 Yamazaki, 2016, Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G), Ann Oncol, 27, 1539, 10.1093/annonc/mdw206 Shui, 2018, Triplet chemotherapy (FOLFOXIRI) plus bevacizumab versus doublet chemotherapy (FOLFOX/FOLFIRI) plus bevacizumab in conversion therapy for metastatic colorectal cancer: a meta-analysis, Cell Physiol Biochem, 48, 1870, 10.1159/000492508 Robinson, 2010, Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker, Semin Nephrol, 30, 591, 10.1016/j.semnephrol.2010.09.007 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 Bennouna, 2013, Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial, Lancet Oncol, 14, 29, 10.1016/S1470-2045(12)70477-1 Masi, 2015, Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial, Ann Oncol, 26, 724, 10.1093/annonc/mdv012 Giantonio, 2007, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200, J Clin Oncol, 25, 1539, 10.1200/JCO.2006.09.6305